Neoplasms, Second Primary  >>  Caprelsa (vandetanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
MetAction, NCT02142036 / 2013-001363-23: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy

Completed
2
50
Europe
EMA-approved ATI based targeted therapy, Cetuximab, Panitumumab, Gefitinib, Erlotinib, Crizotinib, Trastuzumab, Lapatinib, Imatinib, Dasatinib, Nilotinib, Vemurafenib, Everolimus, Temsirolimus, Sunitinib, Ruxolitinib, Vandetanib., Afatinib, Dabrafenib
Oslo University Hospital, The Research Council of Norway
Metastatic Cancer
08/18
08/18

Download Options